现代仪器与医疗

核医学诊疗内照射剂量评估软件差异的规范化建议

PDF下载

梁仔龙 ¹ , 李原 ¹ , 耿建华 ²^,^* , 王茜 ¹^,^*

现代仪器与医疗 | 核医学与分子影像专栏 2026,32(1): 19-26

收起

现代仪器与医疗 |核医学与分子影像专栏 2026 , 32 (1) : 19 -26

核医学诊疗内照射剂量评估软件差异的规范化建议

全屏

梁仔龙¹, 李原¹, 耿建华²^,^*, 王茜¹^,^*

作者信息

^1.北京大学人民医院核医学科，北京　100044

^2.国家癌症中心，国家肿瘤临床医学研究中心，中国医学科学院肿瘤医院核医学科，北京　100730

通讯作者:

耿建华，女，博士研究生，研究员，研究方向：核医学质量控制，放射防护，核医学图像处理及核医学内照射剂量

王茜，女，博士研究生，主任医师，研究方向：甲亢及内分泌肿瘤的核素诊断与治疗，PET/CT及SPECT/CT的影像诊断，PET/CT在发热待查中的应用

作者简介:

梁仔龙，男，本科，研究方向：核医学内照射剂量

Standardized recommendations for discrepancies in internal dosimetry assessment software on nuclear medicine diagnosis and therapy

Zilong Liang¹, Yuan Li¹, Jianhua Geng²^,^*, Qian Wang¹^,^*

Affiliations

^1.Department of Nuclear Medicine, Peking University People's Hospital, Beijing 100044, China

^2.National Cancer Center, National Clinical Research Center for Cancer, Department of Nuclear Medicine, Cancer Hospital Chinese Academy of Medical Sciences, Beijing 100730, China

出版时间: 2026-02-10 doi: 10.11876/mimt202601003

文章导航

摘要

收起

目的

探讨核医学内照射剂量估算软件之间结果差异的主要来源，并提出可用于跨中心比较与结果复现的规范化建议。

方法

回顾性分析国际放射防护委员会（International Commission on Radiological Protection，ICRP）关于核医学诊疗内照射的相关医学研究文献，总结分析核医学诊疗内照射剂量评估差异产生的原因。

结果

本综述将现有的软件分为参考体模范式软件和个体化分析范式软件两大类，从体模与源/靶区定义、物理/生理数据库版本、时间-活度曲线（time-activity curve，TAC）至时间积分活度（time-integrated activity，TIA）/时间积分活度系数（time-integrated activity coefficient，TIAC）的数据处理与积分规则、计算引擎与关键假设、输出指标定义、数据处理与可追溯性6个方面分析不同软件估算结果差异的来源及其影响，并提出可行的核医学内照射剂量估算参数披露建议。

结论

建议核医学诊疗进行内照射剂量评估时披露计算相关参数信息，以提高研究的可解释性、可复现性和跨中心可比性，为临床应用与多中心合作提供更可靠的方法学基础。

关键词

核医学 / 内照射 / 剂量学 / 参数披露

Abstract

收起

Objective

To investigate the primary sources of discrepancies in results among internal dosimetry estimation software in nuclear medicine and to propose standardized recommendations for cross-center comparison and result reproducibility.

Methods

A retrospective analysis was conducted on relevant medical research literatures by the International Commission on Radiological Protection concerning internal dosimetry in nuclear medicine diagnosis and therapy. The causes of variability in internal dose assessment in nuclear medicine were summarized and analyzed.

Results

This review categorizes existing software into two paradigms: reference phantom-based software and individualized analysis-based software. The sources and impacts of discrepancies in estimation results among different software were analyzed from six aspects: phantom and source/target region definitions, versions of physical/physiological databases, data processing and integration rules from time-activity curve (TAC) to time-integrated activity (TIA)/time-integrated activity coefficient (TIAC), calculation engines and key assumptions, definitions of output metrics, and data processing and traceability. Feasible recommendations for parameter disclosure in nuclear medicine internal dosimetry estimation are proposed.

Conclusion

It is recommended to disclose relevant parameter information when performing internal dosimetry assessments in nuclear medicine to enhance the interpretability, reproducibility, and cross-center comparability of the research, thereby providing a more reliable methodological foundation for clinical applications and multicenter collaborations.

Key words

Nuclear medicine / Internal radiation / Dosimetry / Parameter disclosure

引用本文

梁仔龙, 李原, 耿建华, 王茜. 核医学诊疗内照射剂量评估软件差异的规范化建议. 现代仪器与医疗, 2026 , 32 (1) : 19 -26 . DOI: 10.11876/mimt202601003

Zilong Liang, Yuan Li, Jianhua Geng, Qian Wang. Standardized recommendations for discrepancies in internal dosimetry assessment software on nuclear medicine diagnosis and therapy[J]. Modern Instruments & Medical Treatment, 2026 , 32 (1) : 19 -26 . DOI: 10.11876/mimt202601003

参考文献

收起

文献

收起

参考文献引证文献

排序方式：

[1]

1962 supplement to report of committee II on permissible dose for internal radiation (ICRP publication 2)[J]. Annals of the ICRP/ICRP Publication, 1964, 6(1): 37-70.

[2]

ICRP. The 2007 recommendations of the International Commission on Radiological Protection: ICRP publication 103[J]. Annals of the ICRP, 2007, 37(2-4): 1-332.

[3]

ICRP. Adult reference computational phantoms: ICRP publication 110[J]. Annals of the ICRP, 2009, 39(2): 1-164.

[4]

Bolch W E, Jokisch D, Zankl M, et al. ICRP publication 133: the ICRP computational framework for internal dose assessment for reference adults: specific absorbed fractions[J]. Annals of the ICRP, 2016, 45(2): 5-73.

[5]

Uribe C, Peterson A, Van B, et al. An international study of factors affecting variability of dosimetry calculations, part 1: design and early results of the SNMMI dosimetry challenge[J]. Journal of Nuclear Medicine, 2021, 62(S3): 36S-47S.

[6]

Stokke C, Gnesin S, Tran-Gia J, et al. EANM guidance document: dosimetry for first-in-human studies and early phase clinical trials[J]. European Journal of Nuclear Medicine and Molecular Imaging, 2024, 51(5): 1268-1286.

[7]

Zanzonico P. Dosimetry for radiopharmaceutical therapy: practical implementation, from the AJR special series on quantitative imaging[J]. American Journal of Roentgenology, 2025, 225(5): e2431873.

[8]

ICRP. Recommendations of the International Commission on Radiological Protection: ICRP publication 26[J]. Annals of the ICRP, 1977, 1(3): 1-51.

[9]

1990 Recommendations of the International Commission on Radiological Protection: ICRP publication 60[J]. Annals of the ICRP, 1991, 21(1-3): 1-201.

[10]

Basic anatomical and physiological data for use in radiological protection: reference values. A report of age- and gender-related differences in the anatomical and physiological characteristics of reference individuals: ICRP publication 89[J]. Annals of the ICRP, 2002, 32(3-4): 5-265.

[11]

Eckerman K, Endo A. Nuclear decay data for dosimetric calculations: ICRP publication 107[J]. Annals of the ICRP, 2008, 38(3): 7-96.

[12]

Bolch W E, Eckerman K, Endo A. Paediatric reference computational phantoms: ICRP publication 143[J]. Annals of the ICRP, 2020, 49(1): 5-297.

[13]

ICRP. Specific absorbed fractions for reference paediatric individuals: ICRP publication 155[J]. Annals of the ICRP, 2023, 52(4): 9-98.

[14]

Zankl M, Becker J, Lee C, et al. Computational phantoms, ICRP/ICRU, and further developments[J]. Annals of the ICRP, 2018, 47(3-4): 35-44.

[15]

Gear J. Milestones in dosimetry for nuclear medicine therapy[J]. British Journal of Radiology, 2022, 95(1135): 20220056.

[16]

易艳玲, 赵超, 杨莉, 等. 临床核医学诊断所致患者内照射剂量估算软件的开发[J]. 中国辐射卫生, 2013, 22(2): 132-134.

[17]

孙亮, 李士骏. 放射性药物内照射剂量计算软件(Ⅰ): 源器官衰变数的计算[J]. 辐射研究与辐射工艺学报, 2002, 20(3): 204-208.

[18]

Lee C. A review of organ dose calculation methods and tools for patients undergoing diagnostic nuclear medicine procedures[J]. Journal of Radiation Protection and Research, 2024, 49(1): 1-18.

[19]

ICRP. Radiation dose to patients from radiopharmaceuticals: a compendium of current information related to frequently used substances: ICRP publication 128[J]. Annals of the ICRP, 2015, 44(2S): 1-335.

[20]

Stabin M G, Sparks R B, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine[J]. Journal of Nuclear Medicine, 2005, 46(6): 1023-1027.

[21]

Andersson M, Johansson L, Eckerman K, et al. IDAC-Dose 2.1, an internal dosimetry program for diagnostic nuclear medicine based on the ICRP adult reference voxel phantoms[J]. EJNMMI Research, 2017, 7(1): 88.

[22]

Andersson M, Eckerman K Mattsson S. IDAC-Dose 2.2, an internal dosimetry software for diagnostic nuclear medicine based on the latest ICRP adult and paediatric reference computational phantoms[J]. EJNMMI Physics, 2025, 12(1): 56.

[23]

Kesner A L, Carter L M, Ramos J C O, et al. MIRD pamphlet no. 28, part 1: MIRDcalc-a software tool for medical internal radiation dosimetry[J]. Journal of Nuclear Medicine, 2023, 64(7): 1117-1124.

[24]

Carter L M, Ramos J C O, Olguin E A, et al. MIRD pamphlet no. 28, part 2: comparative evaluation of MIRDcalc dosimetry software across a compendium of diagnostic radiopharmaceuticals[J]. Journal of Nuclear Medicine, 2023, 64(8): 1295-1303.

[25]

Chauvin M, Borys D, Botta F, et al. OpenDose: open-access resource for nuclear medicine dosimetry[J]. Journal of Nuclear Medicine, 2020, 61(10): 1514-1519.

[26]

Eckerman K F, Leggett R W, Cristy M, et al. User's guide to the DCAL system: ORNL/TM-2001/190[R/OL]. (2006-08-01) [2026-01-28]. https://www.ornl.gov/sites/default/files/dcalman.pdf.

[27]

Grassi E, Finocchiaro D, Fioroni F, et al. Patient-specific dosimetry evaluations in Theranostics software for internal radiotherapy[J]. Applied Sciences, 2024, 14(16): 7345.

[28]

Jan S, Santin G, Strul D, et al. GATE: a simulation toolkit for PET and SPECT[J]. Physics in Medicine and Biology, 2004, 49(19): 4543-4561.

[29]

Sato T, Furuta T, Sasaki H, et al. Establishment of a practical methodology for evaluating equieffective dose of individual patients based on RT-PHITS[J]. EJNMMI Physics, 2025, 12(1): 28.

[30]

Maroufpour S, Aryana K, Nasseri S, et al. Validation of dosimetry programs (Olinda & IDAC) for evaluation of absorption dose in ¹⁷⁷LuPSMA therapy of metastatic castration-resistant prostate cancer (mCRPC) using Monte Carlo simulation[J]. EJNMMI Physics, 2024, 11(1): 102.

[31]

Sandgren K, Johansson L, Axelsson J, et al. Radiation dosimetry of [⁶⁸Ga] PSMA-11 in low-risk prostate cancer patients[J]. EJNMMI Physics, 2019, 6(1): 2.

[32]

Oliver S, Cases J, Juste B, et al. Determination of organ doses in thyroid treatments with radioactive iodine by Monte Carlo simulation[J]. Radiation Physics and Chemistry, 2024, 221: 111737.

[33]

Seyedabadi A, Porouhan P, Sadoughi H R, et al. Radiation absorbed dose efficacy of 177Lu-DOTATATE in radionuclide therapy of neuroendocrine tumors: a hybrid study of patient and simulation[J]. Radiation Protection Dosimetry, 2025, 201(8): 602-611.

[34]

Ukon N, Zhao S, Washiyama K, et al. Human dosimetry of free ²¹¹At and meta-[²¹¹At] astatobenzylguanidine (²¹¹At-MABG) estimated using preclinical biodistribution from normal mice[J]. EJNMMI Physics, 2020, 7(1): 58.

[35]

马锐垚, 邱睿, 武祯, 等. 核医学治疗中患者的体素级剂量计算[J]. 原子能科学技术, 2023, 57(6): 1253-1259.

[36]

Kwon T E, Han H, Choi C, et al. Enhanced internal dosimetry for alimentary tract organs in nuclear medicine based on the ICRP mesh-type reference phantoms[J]. Radiation Physics and Chemistry, 2024, 224: 112009.

[37]

Wilson S, Osborne D, Long M, et al. Practical tools for patient-specific characterization and dosimetry of radiopharmaceutical Extravasation[J]. Health Physics, 2022, 123(5): 343-347.

[38]

Woo S K. The role of artificial intelligence in advancing theranostics dosimetry for cancer therapy: a review[J]. Nuclear Medicine and Molecular Imaging, 2025, 59(5): 329-341.

[39]

Alshehri A H D. Advancing internal dosimetry in personalized nuclear medicine: toward optimized radiopharmaceutical use in clinical practice[J]. Pharmaceuticals, 2025, 18(11): 1741.

[40]

蔡冶, 曹勤剑, 卫晓峰, 等. BNCT剂量测量与计算方法的研究进展[J]. 核电子学与探测技术, 2025, 45(7): 988-998.

[41]

刘玉连, 张文艺. 核医学工作人员内照射剂量监测研究进展[J]. 中华放射医学与防护杂志, 2021, 41(11): 874-880.

2026年第32卷第1期

PDF下载

引用本文

BibTeX

文章信息

doi: 10.11876/mimt202601003

首发时间：2026-10-23
出版时间：2026-02-10

补充材料

相关文章

文章信息

作者

出版历史

基金

作者信息

^1.北京大学人民医院核医学科，北京　100044

^2.国家癌症中心，国家肿瘤临床医学研究中心，中国医学科学院肿瘤医院核医学科，北京　100730

通讯作者:

耿建华，女，博士研究生，研究员，研究方向：核医学质量控制，放射防护，核医学图像处理及核医学内照射剂量

王茜，女，博士研究生，主任医师，研究方向：甲亢及内分泌肿瘤的核素诊断与治疗，PET/CT及SPECT/CT的影像诊断，PET/CT在发热待查中的应用

参考文献

分享链接

https://castjournals.cast.org.cn/joweb/xdyqyyl/CN/10.11876/mimt202601003

分享至

全文二维码

扫描看全文

引用本文

BibTeX

本文的引用情况

2种不同金属材料的力学参数

科 Family	属数 Number of genus	种数 Number of species	占总种数比例 Percentage of total species (%)	属 Genus	种数 Number of species	占总种数比例 Percentage of total species (%)
鹅膏菌科Amanitaceae	2	11	5.26	鹅膏菌属 Amanita	10	4.78
小菇科 Mycenaceae	2	12	5.74	丝盖伞属 Inocybe	5	2.39
多孔菌科 Polyporaceae	8	14	6.70	蜡蘑属 Laccaria	5	2.39
红菇科 Russulaceae	3	23	11.00	小皮伞属 Marasmius	6	2.87
				小菇属 Mycena	11	5.26
				光柄菇属 Pluteus	5	2.39
				红菇属 Russula	17	8.13
				栓菌属 Trametes	5	2.39

关闭全屏

BibTeX
EndNote
RefWorks
TxT